TNFSF11 and prostate carcinoma: Moreover, in mouse models of melanoma, prostate cancer, and colon cancer, concomitant use of PD‐1/PD‐L1 inhibitors and receptor activator of nuclear factor kappa‐B ligand (RANKL) inhibitors enhanced anti‐metastatic activity and suppressed subcutaneous tumor growth.46, 47